MetaCap

CorMedix (CRMD) vs Lyell Immunopharma (LYEL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Lyell Immunopharma (LYEL) has outperformed CorMedix (CRMD) over the past year, losing 27.9% versus a loss of 45.6%. Over five years, CRMD leads with a +3.9% price change compared with -92.6% for LYEL. Lyell Immunopharma is the larger company by market cap ($441.8 million vs $419.2 million), about 1.1 times the size, while CorMedix is growing revenue faster (+617.0% vs -41.0%).

CorMedix converts more of its revenue into profit, with a net margin of 52.3% versus -762355.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CRMD-45.56%LYEL-27.86%
+110%+21%-69%
Nov 21, 20251 yearNov 20, 2026
CRMD+2.73%LYEL-93.62%
+203%+46%-111%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CRMD versus LYEL key metrics
MetricCRMDLYEL
Share price$5.27$13.80
Market cap$419.16M$441.82M
1-day change+3.74%+1.62%
YTD return-54.69%-55.17%
1-year return-45.56%-27.86%
5-year return+3.94%-92.59%
P/E ratio (TTM)8.23—
Forward P/E15.06—
EPS (TTM)$0.64$-12.61
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$311.71M$36.00K
Revenue growth (YoY)+617.03%-40.98%
Net income (latest FY)$163.06M$-274.45M
Gross margin88.46%—
Operating margin48.17%-748344.44%
Net margin52.31%-762355.56%
52-week high$13.02$45.00
52-week low$4.47$7.20
Distance from 52-week high-59.52%-69.33%
Analyst consensusbuybuy
Avg. price target upside+161.86%+172.68%
Average volume1.44M174.76K
Shares outstanding79.54M32.02M
Employees191161
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • LYEL has outperformed CRMD by 17.7 percentage points over the past year.
  • CorMedix is more profitable, keeping 52.3 cents of every revenue dollar as net income versus -762355.6 cents for Lyell Immunopharma.
  • CorMedix grew revenue faster in its latest fiscal year (+617.03% vs -40.98%).

About CorMedix

CRMD stock →

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.

Health Care · Biotechnology: Pharmaceutical Preparations · 191 employees

About Lyell Immunopharma

LYEL stock →

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 161 employees

CRMD vs LYEL FAQ

Which is bigger, CorMedix or Lyell Immunopharma?

Lyell Immunopharma (LYEL) is larger, with a market capitalization of $441.82M compared with $419.16M for CorMedix (CRMD).

Which stock has performed better over the past year, CRMD or LYEL?

LYEL returned -27.86% over the past 12 months, compared with -45.56% for CRMD (price return, excluding dividends). Past performance does not predict future results.

Are CorMedix and Lyell Immunopharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons